Replies to post #13 on $Amazing $Biotech & $olid $Microcap $tocks

[ash111]

ADHD 2.15 +2.4%, Full DD: Cash, marketable securities, and deposits totaled $54.3 million at 
September 30, 2016 compared with $61.1 million at June 30, 2016 and $69.7 million at the end of 2015.

Recent Presentation highlights:

1. Cash Position support activity thru mid-2018.
2. IP Portfolio- 50 Registered Patents, Protection extents to 2028.
3. 2015 total ADHD sales in US: $9.6B

http://seekingalpha.com/article/4024599-alcobra-adhd-investor-presentation-slideshow

27,562,795  o/s. a/o September 30,2016.

Solid Balance sheet: Total current assets     $52m Total current liabilities     $3.3m

Ratio of 15.7 (Very Solid).

A strong Ownership -Institutional Holdings
63.15%, including Baker Bros : http://www.nasdaq.com/symbol/adhd/ownership-summary

Worst Scenario already priced in, Share price near 52 wk. low. 01/13/2017 Phase 3:
Clinical hold placed September 29, 2016. Noted December 14, 2016 that it intends to given an update from its meeting with the FDA in “the coming weeks” - Latest estimated date - January 13, 2017 assuming that “coming weeks” is defined as less than four weeks.

03/31/2017 Phase 2/3:
Phase 2/3 initiated June 2016. Initial top-line data are due 1Q 2017 as per latest company presentation.
http://biopharmcatalyst.com/calendars/fda-calendar

Risk vs Reward + solid Cash Position, could be interesting.